Boston completes Prolieve acquisition:
This article was originally published in Clinica
Executive Summary
Boston Scientific has closed its acquisition of Celsion's Prolieve technology for treating symptomatic benign prostatic hyperplasia. The two companies had agreed to the $60m transaction in April 2007 (see Clinica No 1253, p 12). Celsion will use the proceeds to fund its ThermoDox liver cancer drug programme.